arrow
T

Tahany Awad

ferring pharmaceuticals a/s, kastrup, denmark
H指数:12
被引数:1,126

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Patient-reported benefits of colonoscopicallyadministered microbiota restoration therapy: a qualitative study of adult patients with recurrent Clostridioides difficile infection

经结肠镜给药的微生物群恢复疗法的患者报告获益:一项关于成人复发性<i>Clostridioides difficile</i>感染患者的定性研究

2025-11-140
OA
Prevention of recurrent Clostridioides difficile infection by fecal microbiota, live-jslm (REBYOTA ® ) administered via colonoscopy: 6-month data from the single-arm phase IIIb CDI-SCOPE trial

通过粪便微生物群,活菌制剂-jslm (REBYOTA<sup>®</sup>) 经结肠镜给药预防复发性 <i>Clostridioides difficile</i> 感染:单臂IIIb期CDI-SCOPE试验的6个月数据

2025-11-090
OA
Safety and effectiveness of fecal microbiota, live-jslm (REBYOTA®) administered by colonoscopy for prevention of recurrent Clostridioides difficile infection: 8-week results from CDI-SCOPE, a single-arm, phase IIIb trial

经结肠镜给药的活菌制剂粪菌移植 (live-jslm, REBYOTA®) 对预防复发性难辨梭菌感染的安全性与有效性:来自CDI-SCOPE单臂、IIIb期试验的8周结果

2025-04-220
OA